ACADIA Pharmaceuticals is trading 4.02% down at $18.63 on October 13, 2026, with no new company-specific announcement clearly explaining the intraday decline.

  • The shares are near a 52-week low, and biotech shares are under pressure; neither establishes a specific cause.
  • Investors are weighing September 24 Phase 2 RADIANT results: remlifanserin narrowly missed its primary endpoint but met a key secondary measure. This is background, not a newly reported catalyst for this session.